Recommended Global Neuroscience Conferences
Neurocognitive Disorders 2017
On behalf of Orgnaizing Committee invites all the participants from all over the world to attend the prestigious Scientific Conference on Cognitive Disorders during Oct 09-10, 2017 at London, UK which encompass Keynote presentations, Oral Presentation, Poster presentations and Exhibitions
Neurocognitive Disorders 2017 is a global platform to discuss and learn about early detection as well as treatment, care based on Professional standards, and increased research to accomplish cure for all cognitive Disorders. The conference includes leading international experts in Neurocognitive Disorders hospitals specialists, doctors, research scholars and general practitioners form all over the world.
Neurocognitive disorders can affect memory, concentration, Knowledge, language, view, and social cognition. They interfere extremly with a person’s everyday independence in Major Neurocognitive Disorder, but not so in Minor Neurocognitive Disorder.
Track 1: NEUROCOGNITIVE DIORDERS
Neurocognitive disorders are characterized by decline from an attained level of cognitive functioning mainly when physical changes occurs in brain, such as after neurological and mental illness, drug use, or brain injury. The two major degenerative causes of dementia are Alzheimer's disease and vascular dementia. Dementia is usually caused by degeneration in the cerebral cortex, the part of the brain responsible for thoughts, memories, actions, and personality. Death of brain cells in this region leads to the cognitive impairments that characterise dementia. Vascular dementia is the broad term for dementia associated with problems of circulation of blood to the brain.
3rd International Conference on Parkinson’s Disease and Movement Disorders, Sep 25-26, 2017 Chicago, USA; 11thWorld Congress on Neurology and Therapeutics, Mar 27-19,2017 Madrid, Spain; 4th International Conference on Neurodegenerative disorders and Stroke, July 05-06, 2017, Frankfurt, GERMANY; 14th World Congress on Neurology and Neurological Disorders, July 17-18, 2017, Chicago, USA; 13th International Conference on Neurology and Neurosurgery, June 19-21, 2017, Paris, FRANCE, 2ndInternational Brain Stimulation Conference Mar5-8,2017,Barcelona,Spain; BritishNeuroscienceAssociation (BNA) Festival of Neuroscience 2017 Apr 10-13, 2017, Birmingham, United Kingdom; Gottingen 2017 / 12th Gottingen meeting of the German Neuroscience Society Mar 22-25, 2017, Gottingen, Germany; Alzheimer’s disease and Dementia Conference Oct 29-31,2017, Brussels, Belgium; Alzheimer's Association International Conference July 16-20, 2017 London, United Kingdom.
American Psychological Association (APA), Vestibular Disorders Association (VDA), American Psychological Society ( APS), American Payroll Association ( APA ), Association for Psychological Science (APS)
Track 2: COGNITION AND BEHAVIOUR
When nerve cells in the brain are damaged, they can no longer send information to each other in the normal way. This causes changes in the person's behaviour and abilities.Individuals with a moderate-to-severe brain injury often have problems in basic cognitive (thinking) skills such as paying attention, concentrating, and remembering new information and events. They may think slowly, speak slowly and solve problems slowly and confused easily when normal routines are changed or when things become too noisy or hectic around them. They may have speech and language problems, such as trouble finding the right word or understanding others. After brain injury, a person may have trouble with all the complex cognitive activities necessary to be independent and competent in our complex world. The brain processes large amounts of complex information all the time that allows us to function independently in our daily lives. This activity is called executive function because it means being the executive or being in charge of one's own life.
17th World Summit on Positive Psychology, Psychotherapy & Cognitive Behavioral Sciences May 1-3, 2017 Toronto, Ontario, Canada, 16th World Congress on Psychiatry and Psychological Syndromes April 24-25, 2017 Las Vegas, Nevada, USA, 21st World Congress on Neurology and Therapeutics March 15-17, 2018 London , UK , European Student Conference on Behaviour & Cognition 17-18 March 2016 in St Andrews, 19th International Conference on Psychological and Behavioural Sciences Zurich Switzerland, Jan 13-14, 2017, International Conference on Cognitive and Behavioural Psychology 12-13 Feb, 2018
Schizophrenia International Research Society (SRIS), American Delirium Society (ADS), Anxiety and Depression association of America (ADAA), National Association of Alcohol, Drugs and Dependency (NAADD), Canadian Mental Health Association (CMHA)
Dementia is usually caused by degeneration in the cerebral cortex, the part of the brain responsible for thoughts, memories, actions, and personality. Death of brain cells in this region leads to the cognitive impairments that characterise dementia. Causes of dementia include head injury, brain tumours, infections, hormone disorders, metabolic disorders, hypoxia, nutritional deficiencies, drug abuse, or chronic alcoholism. Unfortunately, most disorders associated with dementia are progressive ,degenerative and irreversible. The two major degenerative causes of dementia are Alzheimer's disease and vascular dementia Multiple neuropathologic processes may underlie dementia, including both neurodegenerative diseases and vascular disease. Dementia is most common in elderly individuals, with advancing age being the strongest risk factor.
9th International Conference on Alzheimer’s Disease & Dementia October 16-18, 2017 Rome, Italy, 11th International Conference on Vascular Dementia February 22-23, 2018 Paris, France, 7th International Conference on Dementia & Care Practice Toronto, Ontario, Canada August 14-16, 2017, 8th International Conference on Dementia and Dementia Care , Sept 18-19, 2017, Dublin, Ireland, International Congress of Parkinson's Disease and Movement Disorders, 04-08, June 2017, Vancouver, Canada, International Alzheimer's Disease Conference, 26 – 27 May 2017 Hong Kong, China, Alzheimer’s Society Annual Conference 18 May 2017 London, England, Dementia and Cognition: A Vascular Perspective 08 – 09 May 2017 Montreal, Canada.
Related Associations :
Dementia Society of America (DSA)The Association for Frontotemporal Degeneration (AFD)International Huntington’s Association (IHA), European Huntington Association (EHA), American Parkinson Disease Association (APDA)
Track 4 : VASCULAR DEMENTIA
Vascular dementia is the broad term for dementia associated with problems of circulation of blood to the brain. Vascular brain injury (VBI) is widely recognized as a common cause of cognitive impairment (vascular cognitive impairment) culminating in vascular dementia. Most vascular dementia cases are sporadic and share risk factors with peripheral vascular disease. Vascular dementia is not a single disease; it is a group of syndromes relating to different vascular mechanisms.
11th International Conference on Vascular Dementia , February 22-23, 2018 Paris, France, 9th International Conference on Alzheimer’s and Dementia, Oct 16-18, 2017, Rome, Italy, 8th International Conference on Dementia and Dementia Care, Sep 18-19, 2017, Dublin , Ireland, International Colloquium on Alzheimer’s and Dementia, Nov 29-30, 2017, Brisbane, Australia, Vascular Dementia 10th International Congress 2017, Gdansk, 7th International Conference on Dementia and Care Practise, Aug 14-16, 2017, Toronto, Canada, International Congress on Vascular Dementia, 11 May, 2017.
Related Associations :
Vascular Dementia Stroke Association (VDSA)Vascular Dementia Alzheimer Association (VDAA), National Stroke Association (NSA), Lewy Body Association (LBA), American Parkinson Disease Association (APDA).
Track 5: PATHOGENESIS OF COGNITIVE DISORDERS
The classic Neuro pathological signs of Cognitive disorders are amyloid plaques and neurofibrillary tangles. Plaques consist largely of the protein fragment beta-amyloid. This fragment is produced from a "parent" molecule called amyloid precursor protein. Tangles consist of tau, a protein normally involved in maintaining the internal structure of the nerve cell. While tau is normally modified by phosphorylation, or the attachment of phosphate molecules, excessive phosphorylation appears to contribute to tangle formation and prevents the protein from carrying out its normal functions. Oxidative stress, or damage to cellular structures by toxic oxygen molecules called free radicals, is also regarded as a pathology characteristic of Alzheimer’s. Individuals with Alzheimer’s typically experience brain inflammation. Many of the oldest patients with Alzheimer’s show signs of cerebrovascular disease in addition to "classic" Alzheimer's neuropathology.
3rd International Conference on Parkinson’s Disease and Movement Disorders, Sep 25-26, 2017 Chicago, USA; 11th World Congress on Neurology andTherapeutics, Mar 27-19,2017 Madrid, Spain; 4th International Conference on Neurodegenerative disorders and Stroke, July 05-06, 2017, Frankfurt, GERMANY; 14th World Congress on Neurology and Neurological Disorders, July 17-18, 2017, Chicago, USA; 13th International Conference on Neurology and Neurosurgery, June 19-21, 2017, Paris, FRANCE 2nd International Brain Stimulation Conference Mar 5-8, 2017,Barcelona,Spain; British Neuroscience Association (BNA) Festival of Neuroscience 2017 Apr 10-13, 2017, Birmingham, United Kingdom; Gottingen 2017 / 12th Gottingen meeting of the German Neuroscience Society Mar 22-25, 2017, Gottingen, Germany; Alzheimer’s disease and Dementia Conference Oct 29-31,2017, Brussels, Belgium; Alzheimer's Association International Conference July 16-20, 2017 London, United Kingdom.
National Multiple sclerosis society (NMSS), Lewy Body Dementia Association (LBDA) Association of prior stroke with Cognitive function and Cognitive impairment (ASCCI), Vascular Dementia –Alzheimer’s Association (VDAA)
Track 6: COGNITIVE NEUROSCIENCE
Cognitive neuroscience is the scientific field that is concerned with the study of the biological processes and aspects that underlie cognition, with a specific focus on the neural connections in the brain which are involved in mental processes. It addresses the questions of how cognitive activities are affected or controlled by neural circuits in the brain. Cognitive neuroscience is a branch of both neuroscience and psychology, overlapping with disciplines such as physiological psychology, cognitive psychology, and neuropsychology. Cognitive neuroscience relies upon theories in cognitive science coupled with evidence from Neuropsychology, and Computational modelling .
17th Global Neuroscience Conference, October 16-17, 2017 Osaka, Japan, 17th World Summit on Positive Psychology, Psychotherapy & Cognitive Behavioral Sciences,May01-03,2017 Toronto,Ontario,Canada, 25th World Summit on Psychology, Psychiatry & Psychotherapy, October 19-20, 2017 San Francisco, California, USA, 2nd International Congress on Forensic Science and Psychology,October12-13,2017 London, UK, 2nd International Conference on Counseling Psychology, October 16-17, 2017 Osaka, Japan, 32nd International Conference of Alzheimer's Disease, Apr 26-29 2017, Kyoto,Japan, 19thInternational Conference on Psychological and Behavioural Sciences Zurich Switzerland, Jan 13-14, 2017, International Conference on Cognitive and Behavioural Psychology 12-13 Feb, 2018.
Related Associations :
National Institute of Mental Health (NIMH), National Alliance on Mental Illness (NAMI),National Institute of Neurological dis orders and Stroke (NINS), American Academy of Neurological and Orthopaedic Surgeons (AANOS), American Academy of Neurology (AAN).
Track 7: NEURODEGENERATION AND AGING
A Neurodegenerative disease includes Alzheimer's, Huntington's, Parkinson's, and the prion maladies, are genetically and pathologically linked to aberrant protein aggregation. AD, the most common type of dementia, is typically sporadic; however, rare mutations in several genes confer early onset. Release of the aggregation-prone peptides Aβ1–40 and Aβ1–42 by endoproteolysis of the amyloid precursor protein (APP) is associated with AD through an unknown mechanism that appears to be associated with Aβ aggregation. Typically, individuals who carry AD-linked mutations present with clinical symptoms during their fifth or sixth decade, while sporadic cases appear after the seventh decade. Although aggregation-mediated neurodegeneration emerges late in life, it is unclear whether this late onset is mechanistically linked to the aging process.Amyotrophiclateralsclerosis (ALS) is a progressive neurodegenerative disorder of the motor neurons in the spinal cord, brainstem, and motor cortex.
5th International Conference on Brain Disorders and Therapeutics Nov 29 - Dec 01, 2017 Madrid, Spain, 3rd International Conference on Parkinson’s Disease & Movement Disorders, September 25-26, 2017 Chicago, USA, 13th International Conference on Neurology and Neurosurgery, June 19-21, 2017 Paris, France, 21st World Congress on Neurology and Therapeutics, March 15-17, 2018 London, UK, 3rd International Conference on Central Nervous System Disorders & Therapeutics, Oct 02-04, 2017 Vienna, Austria, Alzheimer's Disease International 2017, 26 – 29 April 2017, Kyoto, Japan, American Society on Aging (ASA) 2019 Aging in America Conference , April 15-18, 2019, USA, 4th International Conference: Aging & Cognition, April 20-22, 2017,Switzerland, 2nd Interventions in Aging Conference - Understanding Mechanisms & Compressing Morbidity in Aging Humans, 02-05, March, 2017, Mexico.
American Chronic Pain Association (ACPA), Foundation for Peripheral Neuropathy (FPN), Neuropathy Association, Muscular Dystrophy Association (MDA), Charcot-Marie-Tooth Association (CMTA), American Society for Peripheral Nerve
Track 8: NEUROPSYCHIATRY
Neuropsychiatry is a branch of medicine that deals with mental disorders attributable to diseases of the nervous system. It preceded the current disciplines of psychiatry and neurology. However, psychiatry and neurology subsequently split apart and are typically practiced separately. Nevertheless, Neuropsychiatry has become a growing subspecialty of psychiatry and it is also closely related to the fields of neuropsychology and Behavioral Neurology, addresses clinical problems of cognition and/or behaviour caused by brain injury or brain disease. The division’s neuropsychiatry works collaboratively with the department’s neurologists to treat and manage the emotional and cognitive symptoms of neurological diseases. Such symptoms can include depression, anxiety, psychosis, hallucinations, and/or cognitive loss. Treatment can include psychotherapy and/or medication
15th European Neurology Congress, August 29-31, 2017 London, UK, 20th Euro Congress on Psychiatrists and Psychologists, August 07-08, 2017, Rome, Italy, 14th World Congress on Neurology and Neurological Disorders July 17-18, 2017 Chicago, USA, 12th International Conference on Neurology and Neurophysiology, May 18-20, 2017 Munich, Germany, Argentine Psychiatric Association 32nd Annual Congress 2017, APRIL 26-29, 2017, MARDELPLATA, ARGENTINA, RCPSYCH Faculty of Addictions Psychiatry Annual Conference, April 27-28, London, RCPSYCH Faculty of Liason Psychiatry Annual Meeting, May 10-12,2017, London, Royal College of Psychiatrists Eating Disorders Faculty Spring Conference, May 12, 2017, Liverpool.
Related Associations :
American Neuropsychiatric Association (ANA) ,International Neuropsychiatric Association (INA), World Psychiatric Association (WPA),Mood Disorders Society of Canada (MDSC),American Academy of Neurology (AAN)
Track 9: APPROACHES FOR NEURAL DYNAMICS
Neural dynamics is the study of the nervous system's remarkable capacity to change, and, at a systems level, the dynamic interplay between integration and segregation of brain regions enables all aspects of behaviour, including learning, memory, homeostasis and sensorimotor control. Real-time collision-free path planning and tracking control of a nonholonomic mobile robot in a dynamic environment is investigated using a neural dynamics based approach. The real-time robot path is generated through a dynamic neural activity landscape of a topologically organized neural network that represents the changing environment. The dynamics of each neuron is characterized by an additive neural dynamics model. The effectiveness and efficiency of this approach are demonstrated through simulation studies. A new approach to neural dynamics by using combined TMS and EEG recordings.
2ndInternationalConference on Neuro Oncology and Neurosurgery,Apr24-25,2017,Dubai,UAE; 20thInternational Conference on Neuroscience and Neurochemistry, Feb 26-27,2017, Berlin, Germany; 11thInternational Conference on Vascular Dementia, Feb 22-23, 2018, Paris, France; 12thInternational Conference on Neurology and Neurophysiology, May 18-20, 2017, Munich, Germany; 2ndInternational Conference and Exhibition of Dual Diagnosis, May 18-19, 2017, Munich, Germany; American Headache Society 59th Annual scientific meeting, June 8-11, 2017, Boston, US; 2nd International Brain Stimulation Conference Mar 5-8, 2017, Barcelona, Spain; International Brain Stimulation Conference Mar 5 - 8, 2017, Barcelona, Spain.
National Headache Foundation: (NHF), American Headache Society (AHS), Headache and Migraine Organizations (HMO), American Headache and Migraine Association (AHMA), The National Migraine Association (TNMA), Ontario Headache & Migraine Charity.
Track 10:NEUROLOGY NURSING
Neurological Nursing is a very challenging nursing specialty dealing with assessment, nursing diagnosis, and management of many neurological disorders for which nurses provide patient care. They are expected to work at health care clinics, hospitals and Intensive rehabilitation and brain injury units assisting complex Neuro surgeries, or with procedures in Neurointerventional Radiology and even in Clinic research areas. This includes trauma, brain injuries, stroke, seizures, tumours, headaches, infections, and aneurysms, as well as a host of other neurological complexities.
11th World Congress on Neurology and Therapeutics, Mar 27-29, 2017; 2nd International Conference on Neuro Oncology and Neurosurgery, Apr 24-25, 2017, Dubai, UAE; 17th Global Neuroscience Conference, Oct 16-17, 2017, Osaka, Japan; 20th Annual Meeting on Neurology and Neurosurgery, Nov 27-27, 2017, Dubai, UAE; 12th International Conference on Neurology and Neurophysiology, May 18-20, 2017 Munich, Germany; EGYPTIAN NEUROSURGERY Mar 21- 24 2017, Cairo, Egypt; 3rd Neurological disorders Summit, Jul 06-08, 2017, San Francisco, USA; Programming and Reprogramming the brain Munich, Germany; International Brain Stimulation Conference Mar 5 - 8, 2017, Barcelona, Spain; European Neuroconvention June 7-8, 2017, London, UK
American Association of Neuroscience Nurses (AANN),Neuroscience Nursing (NN), Canadian Association of Neuroscience Nurses (CANN), British Association of Neuroscience Nurses (BANN) American Association of Nurse Practitioners (AANP)
Track 11: NON-PHARMACOLOGICAL MANAGEMENT
It is increasingly recognised that pharmacological treatments for dementia should be used as a second-line approach and that non-pharmacological options should, in best practice, pursued first. Non Pharmacological management include Standard therapies, Behavioural therapy, Reality orientation, Validation therapy etc. Reality orientation is one of the most widely used management strategies for dealing with people with dementia. It aims to help people with memory loss and disorientation by reminding them of facts about themselves and their environment.
17th World Summit on Positive Psychology, Psychotherapy & Cognitive Behavioral Sciences, May 1-3, 2017 Toronto, Ontario, Canada, 3rd International Conference on Parkinson’s Disease and Movement Disorders, Sep 25-26, 2017, Chicago, USA; 3rd International Conference on Neurological disorders and Brain Injury, Apr18-19, 2017, London, UK; 18th Neurology and Neurosurgery Conference, Nov 13-15, 2017, Athens, Germany; 9th International Conference on Alzheimer’s disease and Dementia, Oct 16-18, 2017, Rome, Italy; 20th Annual Meeting on Neurology and Neurosurgery, Nov 27-27, 2017, Dubai, UAE; Movement Brain, Body cognition Jul 9-11, 2017, Oxford, UK; 19th International conference on Parkinson’s Disease and Movement Disorders, May 25-26, 2017, London, UK; Perceptorship of Movement disorders Apr 06th , 2017, Cairo, Egypt; Parkinson’s disease and other Movement disorders, Apr 07-08, 2017,Yeravan, Armenia; Basic course in movement disorders 19th , 2017, Lagos, Nigeria.
Association for Behavioral and Cognitive Therapies (ABCT),Japanese Association of Behaviour Therapy (JABT),Association for advancement of Behaviour therapy (ABT),Jersey Alzheimer’s Association (JAA), International Association for Cognitive Psychotherapy (IACP)
Track 12: NEUROPHARMACEUTICS
A drug used to treat Neuropsychiatric, Neuropsychological, or Nervous-system disorders. Neuro-pharmaceutics focuses on identification of therapeutic targets, and then translating those discoveries into drug and therapy development. Research in Neuropharmaceutics includes: drug discovery for limiting high frequency activity in Epilepsy; drug transport proteins that control drug distribution to target tissues; spinal delivery of analgesics to chronic pain treatment; drugs for the treatment of depression, bipolar disorder, and schizophrenia; intranasal delivery methods for the treatment of Alzheimer’s disease; development of strategies to evaluate therapeutics on preclinical models of Alzheimer’s and Parkinson’s disease; anti-atherogenic and anti-diabetic therapies for the prevention and treatment of AD and other age-related dementias; and development of analgesic agents for chronic pain
5th International Conference and Exhibition on Pharmacology and Ethno pharmacology, Mar 23-25, 2017, Orlando, USA; 11th World Congress on Neurology and Therapeutics, Mar 27-29, 2017, Madrid, SPAIN; 12th International Conference on Neurology and Neurophysiology, May 18-20, 2017, Munich, Germany; 17th Global Neuroscience Conference, Oct 16-17, 2017, Osaka, Japan; 5th International Conference on Brain disorders and Therapeutics, Nov 6-8, 2017, Madrid, Spain; World Congress On Neurology And Brain Disorders, Sep 4- 6, 2017,Milan,Italy; 23RD WORLD CONGRESS OF NEUROLOGY Sep 16-21, 2017, Tokyo, Japan; 2nd International Brain Stimulation Conference Mar 5-8, 2017, in Barcelona, Spain; Movement Brain, Body cognition, Jul 9-11, 2017, Oxford, UK; International Brain Stimulation Conference, Mar 5 - 8, 2017, Barcelona, Spain.
The Brain Association for Psychopharmacology (BAP), American Association for Clinical Psychopharmacology (AACP), American Psychiatric Association (APA), American College of Neuropsychopharmacology (ACNP) , American Society for Pharmacology and Experimental Therapeutics (ASPET) , American Academy of Neurology (AAN)
Track 13: NEUROTHERAPEUTICS
It is an older term for the treatment of disorders that affect the nervous system which psychological, psychiatric, and nervous disorders. Neurotherapeutics is a quarterly peer-reviewed medical journal covering research on experimental treatments of neurological disorders. There is a profound increase in the diagnostics procedure and drug discovery in the field of Neurology. It includes Stem cells and treatment, Nerve injury and repair Clinical Case report, Neurogenesis, cell and gene based approach and Neurotransmitter release and cell repair.
3rd International Conference on Central Nervous system disorders and Therapeutics, 0ct 02-04, 2017, Vienna, Austria; 11th World Congress on Neurology and Therapeutics, Mar 27-29, 2017, Madrid, SPAIN; 15th European Neurology Congress, Aug 29-31, 2017, London, UK; 3rd International Conference on Neurological disorders and Brain Injury, Apr 18-19, 2017, London, UK; 11th Annual Pain and Migraine Therapeutics Summit, Sept 27-28, 2017, San Diego, US; 2nd International Brain Stimulation Conference Mar 5-8, 2017, in Barcelona, Spain; 3rd Neurological disorders Summit, Jul 06-08, 2017, San Francisco, USA; Royal College of Psychiatrists: Eating disorders faculty spring Conference May 12th , 2017, Liverpool, UK.
American Society for Experimental Neurotherapeutics (ASEN), Neurologist Association, National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Alternative Medicine (NCCAM).
ConferenceSeries Ltd invites all the participants from all over the world to attend ‘Neurocognitive Disorders 2017 during October 09-10, 2017 at London, UK which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.
Neurocognitive disorders includes Alzheimer’s disease, is one of the biggest global public health challenges facing our generation. Worldwide, at least 46 million people are living with dementia this number is expected to double by 2030 and more than triple by 2050 to 116 million. Much of the increase will be in developing countries like Western Europe and North America. Already 62% of people with dementia live in developing countries. Today, over 35 million people worldwide currently live with the condition. This number is expected to double by 2030 and more than triple by 2050 to 116 million. No treatments available to slow or stop the brain damage caused by Alzheimer’s disease, several medications can temporarily help improve the symptoms of dementia for some people. In two decades, it is estimated that 1.4 million Canadians will have dementia, costing the economy almost $300 billion per year. Globally, dementia cost $600 billion a year.
The term Dementia describes a loss of mental ability (cognitive impairment) associated with gradual death of brain cells. Vascular Dementia can be caused by a number of different diseases, usually neurodegenerative diseases, such as Alzheimer's disease, front temporal dementia and dementia with Lewy bodies. Vascular dementia is caused when the brain's blood supply is restricted or stopped, leading brain cells to die.
Delirium is defined as a transient, usually reversible, cause of cerebral dysfunction and manifests clinically with a wide range of neuropsychiatric abnormalities. It can occur at any age, but it occurs more commonly in patients who are elderly and have compromised mental status.
Delirium occurs in 30% of those in emergency departments. Occurrence rates vary from 11-42% and it is the most common complication of hospitalization in the elderly population. The incidence is also higher in those with pre-existing cognitive impairment. The prevalence is higher in patients with malignancy and HIV. Despite these facts, delirium remains under diagnosed and poorly managed - only 20-50% is recognized by healthcare professionals.
Why to attend?
Neurocognitive disorders 2017 will provide an opportunity for all stakeholders working on Alzheimer’s disease and Dementia to talk about their work. Neurocognitive disorders will congregate renowned speakers, principal investigators, experts, neurologist’s and Dementia researchers from both academia and health care industry will join together to discuss their views and research. The conference will be comprised of sessions by world class experts in the field of neurology. In Neurocognitive disorders international symposiums, B2B meetings, international workshops will also be organized to discuss the specific topics in the field of Dementia and Neurology.
- Neurologists and Directors
- Health care professionals
- Industrial Experts
- Nutritional Scientists
- Lecturers and Students from Academia in the study of Dementia
- Students from Academia in the research of Neurology
It is our pleasure to welcome you to the Neurocognitive disorders 2017 to be held in London, UK from October 09-10, 2017.
The organizing committee is gearing up for an exciting and informative program on a variety of topics, poster presentations and various programs for participants from all over the world. Unsurpassed substantiation cure for Neurocognitive disorders clearly shows that the close association of families and careers in the care of their loved ones is key to improving early revealing of Vascular Dementia, renewal to a healthy weight and sustaining long term wellbeing.
This conference will increase knowledge, provide support, assist learning and allow to seek out applicable services and to develop the best environment to support recovery from these complex and devastating diseases.
Neurocognitive disorders are characterized by decline from an attained level of cognitive functioning mainly when physical changes can be seen to have occurred in brain, such as after neurological and mental illness, drug use, or brain injury. Neurocognitive disorders (NCDs) are a category of conditions that include dementia, amnesia, Alzheimer’s disease, Mild cognitive impairment, Attention deficit hyperactive disorder, Hallucinogen persisting perception disorder, cerebellar cognitive affective syndrome, post-operative cognitive dysfunction, HIV associated neurocognitive disorder.
Alzheimer’s disease is the most common form of dementia accounting for 50% to 70% of all cases. It mostly occurs in the older people who are 65 years and above. Moreover, growing awareness level regarding its symptoms, such as partial dementia, is projected to boost the demand. Currently, there are an estimated 4 million individuals with dementia in the USA with more than 100 000 deaths annually .The global market for Alzheimer’s disease reached $10.2 billion in 2012. The market is expected to decrease to $9.5 billion in 2017 for a CAGR of -1.5%.
The Alzheimer's Association funds independent investigators worldwide, they have awarded over $335 million to more than 2,250 projects. The global cost of Alzheimer’s and dementia is estimated to be $605 billion, which is equivalent to 1% of the entire world’s gross domestic product.
Aggregate Cost of Care by Payer for Americans Age 65 and Older with Alzheimer‘s Disease and Other Dementias: Medicare $113 Billion, Medicaid $41 Billion, Out of pocket $44 Billion, Other $29 Billion.
Dementia is widely considered the second most common cause of dementia after Alzheimer's disease, accounting for 10 percent of cases. Many experts believe that vascular dementia remains underdiagnosed like Alzheimer's disease even though it's recognized as common. The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.
Amnestic Disorders are a group of disorders that involve loss of memories previously established, loss of the ability to create new memories, or loss of the ability to learn new information.1 In general, Amnestic Disorders are caused by structural or chemical damage to parts of the brain.
People who suffer from Amnestic Disorders usually experience difficulty recalling events that happened in the past or facts they have learned prior to diagnosis. This type of amnesia is known as retrograde amnesia. Some people may also experience symptoms of anterograde amnesia, which involves the inability to learn new facts or retain new memories.
The global amnesia therapeutics market was worth $112m in 2011, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.5% to reach $147m by 2019. This growth is primarily attributed to the increase in the general population and diagnosis rate across the seven major markets (the US, the UK, Japan, Germany, Spain, Italy and France).
Alter G Inc.
Bioxtreme Robotics Rehabilitation
London is the political, economic and cultural capital of Britain, and its world class tourist attractions are renowned across the globe. The Greater London area is bursting with attractions for visitors of all ages. The river Thames runs through the heart of London, from Richmond in the west, through the central London borough of Westminster, to Greenwich in the east. London river cruises and river buses are a great way to see the city. About one third of London is devoted to parks and open spaces, so there are plenty of places to relax on fine days. London is incredibly well-connected, with five international airports and the high-speed Eurostar rail link. More than 50 countries are within a three-hour flight time and 310 international destinations have direct links to London. t is one of the world's leading financial centres and has the fifth- or sixth-largest metropolitan area GDP in the world. It is the world's most-visited city as measured by international arrivals and has the world's largest city airport system measured by passenger traffic. There are about 15 Universities in and around London which are working in the field of Neurological disorder. Around 1000 neurologist, psychiatrist and neurosurgeons are working exclusively on Neurological disorder in London.
Top hospitals in the World
The neurology and neurosurgery category consists of 1358 hospitals
The full list of the top 10 hospitals in the United States for neurology and neurosurgery is as follows:
Mayo Clinic, Rochester, Minnesota
New York–Presbyterian University Hospital of Columbia and Cornell, New York City
Johns Hopkins Hospital, Baltimore, Maryland
Massachusetts General Hospital, Boston
University of California–San Francisco Medical Center
Cleveland Clinic, Ohio
University of California–Los Angeles Medical Center
New York University Langone Medical Center, New York City
Hospitals of the University of Pennsylvania–Penn Presbyterian
North-western Memorial Hospital, Chicago
Top hospitals in Europe
Klinik Pyramide Am See
University Hospital Hamburg-Eppendorf
J.W Goethe University Hospital
Hirslanden Clinique La Colline
Hirslanden Klinik Aarau
J.W Goethe University Hospital
Top hospitals in UK
St Dominics Hospital
National Hospital for Neurology and Neurosurgery
Royal Marsden Hospital
Top hospitals in London
Kings College Hospital
The National Hospital for Neurology and Neurosurgery
The Royal Free
Bart’s and the London Centre for Neurosciences
St George's Hospital
The Wellington Hospital
The London Spinal Injuries Unit
Stoke Mandeville Hospital
St Mary's Hospital
The London Gamma Knife Centre
Top Universities in the World
University College London
University of California--San Francisco
Massachusetts Institute of Technology
Johns Hopkins University
University of California--Los Angeles
University of California--San Diego
University of Oxford
Top Universities in the Europe
University of Cambridge
University College London
Max Planck Society
University of Oxford
King;s College London
University of Edinburgh
Imperial College London
University of Bonn
University of Amsterdam
University of Briston
Top Universities in the UK
University of Sheffield
Oxford Brookes University
University Of Birmingham
UCL (University College London)
University Of Edinburg
Universities in London
University of Greenwich
University of West London
Imperial College London
University College London- UK
King college London –UK
Brunel University London
City University London
Queen Mary, University of London
Associations in the World
Alzheimer’s Foundation of America
World Psychiatric Association
National Institute of Mental Health
National institute of Neurological disorders and Stroke
Epilepsy and Seizure Association of Manitoba
The National Migraine Association
American Association of Neuroscience Nurses
European Society of Neuropharmacology
National Institute of Neurological Disorders and Stroke (NINDS)
Associations in UK
Royal Society of London
International Headache Society
Huntington's disease Association
Brain tumour organizations
National Brain Tumour Society
British neuroscience association
Association for Infant Mental Health
National Association for Mental Health
The Brain injury association
The Neuro Association
Associations in London
Neuro foundation Brain Injury Rehabilitation Trust
Royal Society of London
International Headache Society
Huntington's disease Association
Brain tumour organizations
National Brain Tumour Society
The Neuro Association
On behalf of the Organizing Committee, it is with great pleasure to note that Conference series LLC is organizing the 16th International Conference on Neurology and Neurocognitive Disorders, October 9 – 10, 2017 that will be held in London.
Neurocognitive functions are cognitive functions closely linked to the function of particular areas, neural pathways, or cortical networks in the brain substrate layers of neurological matrix at the cellular and molecular levels. Neurocognitive disorders are characterized by a decline from an attained level of cognitive functioning mainly when physical changes can be seen to have occurred in brain, such as after neurological and mental illness, drug use, or brain injury. Neurocognitive disorders involve impairments in cognitive abilities such as memory, problem solving, and perception, and can seriously affect a person’s quality of life. They comprise a category of conditions that include Alzheimer disease/dementia, amnesia, mild cognitive impairment, attention deficit hyperactive disorder, cerebellar cognitive affective syndrome, post-operative cognitive dysfunction, and HIV-associated neurocognitive disorder. Neurocognitive disorders today represent a major unmet medical need which calls out for urgent attention in bringing forward new and efficacious treatments.
The congress is organized in London, the capital and most populous city of England and the United Kingdom. London, founded by the Romans, has been a major settlement for two millennia. It is a leading global city in the arts, commerce, education, entertainment, fashion, finance, healthcare, media, professional services, and research and development. London is a world cultural capital, with more than 300 languages spoken in the region, and boasts four World Heritage Sites. Moreover, London is home to numerous museums, galleries, libraries and other cultural institutions, including the British Museum, National Gallery, Natural History Museum, Tate Modern, British Library, and West End theatres. I am certain that selecting this venue for the congress will provide a stimulating cultural environment for scientific presentation and exchange.
I hope these 2 days of scientific discussions and presentations by leading world experts as well as new research carried out by young scientists will provide a stimulating terrain for novel drug discovery in both basic and clinical research and pave the road to new therapeutic developments for those affected by neurological disease.
Congress participants, be they basic scientists from academia and industry, clinicians, students and policy makers will no doubt benefit the interactions that will take place in the heart of northwest Italy.
We look forward to welcoming you to London.
Stephen D. Skaper, Ph. D.
University of Padua